Applied Therapeutics Inc
APLT0.458USD
+0.018+3.97%
Market hours （ET）Quotes delayed by 15 min
64.87MMarket Cap
LossP/E TTM
More Details of Applied Therapeutics Inc Company
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Company Info
Ticker SymbolAPLT
Company nameApplied Therapeutics Inc
IPO dateMay 09, 2019
CEOMr. Leslie D. (Les) Funtleyder
Number of employees35
Security typeOrdinary Share
Fiscal year-endMay 09
Address545 Fifth Avenue, Suite 1400
CityNEW YORK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code10017
Phone12122209226
Websitehttps://www.appliedtherapeutics.com/
Ticker SymbolAPLT
IPO dateMay 09, 2019
CEOMr. Leslie D. (Les) Funtleyder
Company Executives
Name
Name/Position
Position
Shareholding
Change
Evan Prescott Bailey ,
Evan Prescott Bailey ,
Chief Medical Officer
Chief Medical Officer
841.67K
--
Mr. Leslie D. (Les) Funtleyder
Mr. Leslie D. (Les) Funtleyder
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
560.81K
+36.51%
Ms. Stacy J. Kanter, J.D.
Ms. Stacy J. Kanter, J.D.
Independent Director
Independent Director
119.25K
+10.42%
Mr. Constantine Chinoporos
Mr. Constantine Chinoporos
Chief Operating Officer and Chief Business Officer
Chief Operating Officer and Chief Business Officer
90.19K
-71.94%
Dr. Jay S. Skyler, M.D.
Dr. Jay S. Skyler, M.D.
Independent Director
Independent Director
65.00K
--
Ms. Catherine Thorpe
Ms. Catherine Thorpe
Interim Chief Accounting Officer
Interim Chief Accounting Officer
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Teena L. Lerner, Ph.D.
Dr. Teena L. Lerner, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Dale Hooks
Mr. Dale Hooks
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Evan Prescott Bailey ,
Evan Prescott Bailey ,
Chief Medical Officer
Chief Medical Officer
841.67K
--
Mr. Leslie D. (Les) Funtleyder
Mr. Leslie D. (Les) Funtleyder
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
560.81K
+36.51%
Ms. Stacy J. Kanter, J.D.
Ms. Stacy J. Kanter, J.D.
Independent Director
Independent Director
119.25K
+10.42%
Mr. Constantine Chinoporos
Mr. Constantine Chinoporos
Chief Operating Officer and Chief Business Officer
Chief Operating Officer and Chief Business Officer
90.19K
-71.94%
Dr. Jay S. Skyler, M.D.
Dr. Jay S. Skyler, M.D.
Independent Director
Independent Director
65.00K
--
Ms. Catherine Thorpe
Ms. Catherine Thorpe
Interim Chief Accounting Officer
Interim Chief Accounting Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, May 20
Updated: Tue, May 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
11.03%
Vestal Point Capital, LP
8.12%
Propel Bio Management, LLC
7.97%
BlackRock Institutional Trust Company, N.A.
6.33%
Knoll Capital Management, LLC
5.51%
Other
61.04%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
11.03%
Vestal Point Capital, LP
8.12%
Propel Bio Management, LLC
7.97%
BlackRock Institutional Trust Company, N.A.
6.33%
Knoll Capital Management, LLC
5.51%
Other
61.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor
33.47%
Hedge Fund
18.25%
Investment Advisor/Hedge Fund
15.40%
Venture Capital
11.90%
Individual Investor
5.70%
Research Firm
2.36%
Private Equity
0.61%
Sovereign Wealth Fund
0.17%
Bank and Trust
0.07%
Other
12.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
297
124.40M
87.87%
-35.48M
2025Q1
297
123.70M
87.51%
-30.40M
2024Q4
287
131.75M
113.23%
-13.70M
2024Q3
251
128.75M
112.47%
+2.21M
2024Q2
218
117.82M
104.34%
+1.65M
2024Q1
214
107.47M
96.19%
+20.49M
2023Q4
204
75.60M
89.15%
+10.52M
2023Q3
201
57.91M
82.88%
+2.25M
2023Q2
197
52.05M
93.62%
+2.03M
2023Q1
199
42.23M
88.25%
+6.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
15.61M
11.03%
+5.23M
+50.40%
Apr 30, 2025
Vestal Point Capital, LP
11.50M
8.12%
--
--
Mar 31, 2025
Propel Bio Management, LLC
11.29M
7.97%
+1.67M
+17.37%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.96M
6.33%
+266.41K
+3.07%
Mar 31, 2025
Knoll Capital Management, LLC
7.80M
5.51%
+2.00M
+34.48%
Mar 31, 2025
VR Adviser, LLC
5.57M
3.93%
-4.42M
-44.27%
Mar 31, 2025
Alexandria Real Estate Equities, Inc.
5.39M
3.81%
-300.00K
-5.27%
Nov 13, 2024
The Vanguard Group, Inc.
5.89M
4.16%
+358.20K
+6.48%
Mar 31, 2025
Shendelman (Shoshana)
4.72M
3.34%
-567.10K
-10.72%
Aug 14, 2024
Schonfeld Strategic Advisors LLC
4.67M
3.3%
-4.09M
-46.66%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Simplify Propel Opportunities ETF
2.06%
Hypatia Women CEO ETF
0%
ProShares Hedge Replication ETF
0%
iShares Biotechnology ETF
0%
SPDR S&P Biotech ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Humankind US Stock ETF
0%
View more
Simplify Propel Opportunities ETF
Proportion2.06%
Hypatia Women CEO ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
SPDR S&P Biotech ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
Humankind US Stock ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
